Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Q2 net loss widens to $35.0 million from $17.7 million

Negative Impact 3 of 5 earnings Written later

Corbus Pharmaceuticals reported a second-quarter 2026 net loss of $35.0 million, or $1.81 per share, up from $17.7 million, or $1.44 per share, a year earlier, as operating expenses rose to $36.2 million. The company said it had $117.9 million in cash, cash equivalents and investments at June 30, 2026, expected to fund operations into 2028, and it announced new executive and board appointments. Shareholders face a larger loss and a higher expense base while the company's two key clinical milestones are expected in September 2026.

Key points

  • Net loss of $35.0 million, or $1.81 per share, for the quarter ended June 30, 2026, versus $17.7 million, or $1.44 per share, a year earlier
  • Operating expenses of $36.2 million, up from $19.2 million, including a $10.0 million development milestone payment for CRB-701
  • Cash, cash equivalents and investments of $117.9 million at June 30, 2026, expected to fund operations into 2028
  • CANYON-1 Phase 1b topline data for CRB-913 in obesity and TEMPO-1 enrollment both expected in September 2026

The filing

CompanyCorbus Pharmaceuticals Holdings, Inc. (CRBP)
Form8-K, current report
Filed with the SECAug 6, 2026, 8:15 AM ET
Accession number0001193125-26-336864

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.